Free Republic

Data from the phase III INTERACT3 study demonstrate that a new combination of treatments for stroke due to intracerebral hemorrhage (ICH) significantly improves the chances of surviving without major disability. The INTERACT3 study is the first-ever randomized controlled trial to show a clearly positive outcome for the treatment of ICH. Timely administration of the new treatment protocol—known as a Care Bundle—centered on the rapid control of high blood pressure, led to improved recovery, lower rates of death, and better overall quality of life. Professor Craig Anderson said, "Despite the high rates of ICH and its severity, there are few proven...

ScienceDaily (Aug. 18, 2008) — A new study conducted by researchers at Children's Hospital & Research Center Oakland shows that a century-old drug, methylene blue, may be able to slow or even cure Alzheimer's and Parkinson's disease. Used at a very low concentration – about the equivalent of a few raindrops in four Olympic-sized swimming pools of water – the drug slows cellular aging and enhances mitochondrial function, potentially allowing those with the diseases to live longer, healthier lives. A paper on the methylene blue study, conducted by Hani Atamna, PhD, and a his team at Children's, was published in...